Analyst Reco. Viridian Therapeutics, Inc.

Equities

VRDN

US92790C1045

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
13.6 ^USD	+5.59%		-4.56%	-37.56%

Apr. 16	Foghorn Therapeutics Names Kristian Humer CFO	MT
Mar. 21	B. Riley Lowers Viridian Therapeutics' PT to $25 From $29, Keeps Buy Rating; Adjusts Model to Reflect Recent Equity Offering, Quarterly Numbers	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

B. Riley Lowers Viridian Therapeutics' PT to $25 From $29, Keeps Buy Rating; Adjusts Model to Reflect Recent Equity Offering, Quarterly Numbers	Mar. 21	MT
Wedbush Lifts Viridian Therapeutics' PT to $40 From $39 on Higher Net Cash, Keeps Outperform Rating	Feb. 28	MT
Wedbush Trims Viridian Therapeutics' Price Target to $39 From $40, Keeps Outperform Rating	Jan. 22	MT
Oppenheimer Raises Viridian Therapeutics Price Target to $36 From $35, Maintains Outperform Rating	Dec. 19	MT
Wedbush Raises Viridian Therapeutics' PT to $40 From $37, Keeps Outperform Rating; Says Remains Among a Top Pick Into 2024	Dec. 19	MT
JMP Securities Adjusts Price Target on Viridian Therapeutics to $38 From $42, Maintains Market Outperform Rating	Nov. 14	MT
B. Riley Lowers Viridian Therapeutics' PT to $29 From $46 to Reflect Dilutive Financing, Lower Peak Sales in TED; Maintains Buy Rating	Nov. 14	MT
RBC Cuts Price Target on Viridian Therapeutics to $35 From $44, Keeps Outperform Rating, Speculative Risk Qualifier	23-10-31	MT
Wedbush Lowers Viridian Therapeutics' PT to $37 From $46 on Heels of Leadership Changes, Private Placement; Keeps Outperform Rating	23-10-31	MT
HC Wainwright Adjusts Price Target on Viridian Therapeutics to $37 From $40, Keeps Buy Rating	23-08-10	MT
Needham Adjusts Price Target on Viridian Therapeutics to $40 From $47, Keeps Buy Rating	23-08-10	MT
Oppenheimer Adjusts Viridian Therapeutics Price Target to $35 From $40, Maintains Outperform Rating	23-08-09	MT
Wells Fargo Adjusts Price Target on Viridian Therapeutics to $39 From $46, Maintains Overweight Rating	23-08-09	MT
Wedbush Lifts Viridian Therapeutics' PT to $46 From $45 After Adjusting Share Count Assumptions, Keeps Outperform Rating	23-08-09	MT
Wedbush Adjusts Viridian Therapeutics' PT to $45 From $48 After Reporting Results For Phase 1/2 Trial for Chronic Thyroid Eye Disease Treatment, Keeps Outperform Rating	23-07-11	MT
BTIG Research Initiates Coverage on Viridian Therapeutics With Buy Rating, $46 Price Target	23-06-14	MT
RBC Initiates Viridian Therapeutics at Outperform With Speculative Risk, Sets Price Target at $44, Sees 'Best Second-Mover Advantage' in Thyroid Eye Disease	23-05-30	MT
JMP Securities Adjusts Price Target on Viridian Therapeutics to $44 From $46, Maintains Market Outperform Rating	23-05-10	MT
Oppenheimer Adjusts Viridian Therapeutics Price Target to $40 From $45, Maintains Outperform Rating	23-05-10	MT
Wedbush Lifts Viridian Therapeutics' Price Target to $48 From $46, Keeps Outperform Rating	23-05-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Viridian Therapeutics, Inc.

Equities

VRDN

US92790C1045

Analyst Reco.

Filters